Neuroprotective effect of hormone replacement therapy: a review of the literature

Climacteric. 2024 Aug;27(4):351-356. doi: 10.1080/13697137.2024.2354759. Epub 2024 Jun 11.

Abstract

Objective: Menopause is a physiological period characterized by the cessation of ovarian activity. Sequential changes during this transition affect multiple systems, including the brain. Sixty percent of women experience cognitive impairment. The objective of this review is to show the neuroprotective effect of hormone replacement therapy (HRT) through the different scales and whether there is a benefit of this in women.

Method: A search was conducted in six databases. Eligibility criteria included women within 10 years of menopause, receiving HRT controlled with placebo, studies lasting more than 6 months and women without a history of chronic underlying pathology.

Results: A total of nine randomized controlled trials met the inclusion criteria. Regarding memory, two studies reported better performance of HRT with a significant odds ratio (OR) of 0.67; regarding attention, one study reported potential improvement in women receiving HRT with a significant OR of 0.87; and neuroimaging assessment found an increase in ventricular volume compared to placebo over a 3-year period.

Conclusions: The early initiation of menopausal HRT in healthy women appears to yield a positive effect on certain cognitive aspects, such as attention and cortical volume in the central nervous system. These findings should be confirmed through future prospective studies.

Keywords: Menopause; cognitive dysfunction; hormone replacement therapy; memory.

Publication types

  • Review

MeSH terms

  • Attention / drug effects
  • Cognition / drug effects
  • Cognitive Dysfunction / drug therapy
  • Cognitive Dysfunction / prevention & control
  • Estrogen Replacement Therapy* / methods
  • Female
  • Hormone Replacement Therapy / methods
  • Humans
  • Memory / drug effects
  • Menopause*
  • Middle Aged
  • Neuroprotective Agents / therapeutic use
  • Randomized Controlled Trials as Topic*

Substances

  • Neuroprotective Agents